ReviewCureus2025
A Systematic Review of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors in the Management of Heart Failure: A Comprehensive Analysis of Cardiovascular Outcomes, Hospitalizations, and Quality of Life.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Diabetes and cancer: therapeutic implications.Cardio-oncology (London, England) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sodium-glucose cotransporter-2 (SGLT2) inhibitors have increasingly established themselves as a vital therapeutic option for heart failure across various levels of left ventricular ejection fraction. Recent studies and clinical trials have shown a significant reduction in adverse cardiovascular events and hospitalization rates among patients with heart failure who are treated with SGLT2 inhibitors. However, the long-term implications of these medications for patient survival in heart failure remain uncertain. The primary aim of this review is to assess the effectiveness of SGLT2 inhibitors in managing heart failure, with particular emphasis on cardiovascular outcomes, hospitalization rates, and quality of life. A systematic search was conducted across multiple electronic databases, including MEDLINE, the Cochrane Library, PubMed, Embase, ClinicalTrials.gov, and CINAHL, to identify high-quality, relevant peer-reviewed studies on SGLT2 inhibitors in heart failure patients. In total, 2,142 records were identified from these databases. After screening, only the records that met the inclusion criteria were retained. Data extraction and analysis were performed by two independent reviewers. Following the screening process, 15 out of the 2,142 studies were included in the final review. These studies demonstrated the effectiveness of SGLT2 inhibitors in supporting long-term survival by improving cardiovascular outcomes, reducing hospitalization rates, and enhancing quality of life. Three key themes emerged from the research: cardiovascular outcomes (five studies), hospitalization rates (five studies), and quality of life (five studies). Overall, SGLT2 inhibitors are effective in the management of heart failure and contribute positively to the long-term survival of patients. They improve cardiovascular outcomes, decrease hospitalization rates, and enhance the overall quality of life for individuals with heart failure. Nevertheless, additional research with longer follow-up periods and larger sample sizes is needed to establish definitive conclusions regarding the long-term efficacy of SGLT2 inhibitors for survival.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.